Antithrombin Market Size, Share, Trends, Growth and Forecast 2032

Table Of Content

Methodology

Free Analysis

Antithrombin is a protein present in the blood stream, which functions as a naturally occurring mild blood thinner. It helps to prevent too much clotting. By inactivating the blood clotting protein thrombin, it blocks the blood clotting mechanism; hence it is known as anti-thrombin. There are two major causes of antithrombin deficiency (AT), inherited or genetic antithrombin deficiency, and acquired antithrombin deficiency. An inherited or genetic deficiency occurred due to a genetic mutation or abnormality, and an acquired deficiency due to some other disease such as liver failure, nephrotic syndrome, metastatic tumors, severe trauma etc.

The global antithrombin market is segmented on the basis of source, application, dosage form, and geographically. Based on the source, the antithrombin market has been segmented as human, and goat milk. The human source segment accounted major shares in 2016. The goat source segment is expected to register high CAGR over the forecast period. The increasing adoption of goat milk for the production of antithrombin is expected to propel the growth of segment over the forecast period. The goat milk derived antithrombin is currently available in Europe and North America. However, the availability of these products in other regions such as Asia Pacific, Middle East & Africa is projected to drive the market share of goat milk source segment over the forecast period.

By Application, the global antithrombin market is segmented as diagnostics, therapeutics, and research. The therapeutics segment is accounted major share in 2016 in global antithrombin market. Availability of therapeutic antithrombin preparation globally with approved indications is the major factor contributing growth of the segment. Moreover, increasing research activities is expected to boost the growth of segment over the forecast period.

By dosage form, the global antithrombin market is segmented as a liquid and lyophilized. The lyophilized segment accounted major share in global antithrombin market in 2016 by dosage form. The lyophilized dosage form has long expiry date and they are widely available. The limited application of liquid antithrombins in research accounts for low market share for the segment. 

By region, the global antithrombin market is segmented into five major regions, North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Europe is expected to remain the dominant region over the forecast period. Early availability of advanced technologies, rising adoption of antithrombin therapies owing to high awareness are the major factors contributing towards the growth of the market in Europe.  North America was the second largest market followed by the Asia Pacific. Asia Pacific market is projected to grow at the highest rate during the forecast period owing to increasing healthcare budgets, and extensive research initiatives in the region. The Middle East and Africa, and Latin America are also expected to experience moderate growth in the years to come.

Some of the key players in global Antithrombin market include Grifols, rEVO Biologics Inc., Shire plc., Kedrion S.p.A., CSL Limited, Scripps Laboratories Inc., and Lee Biosolutions among others. The rising demand for recombinant antithrombins and increasing competition among key players are expected to drive the growth of the market over the forecast period.